A recent cross-sectional study from the US reported a more than two-fold increase in the use of GLP-1 RAs as anti-obesity medications from 2022 to 2023, accompanied by a 25.6% decline in MBS rates during the same period [14]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.